Investment Rating - The report assigns a "Buy" rating for Aladdin (688179) based on its strong potential for growth and strategic acquisitions [10]. Core Insights - The investment in Shanghai Youke is expected to enhance Aladdin's product line in laboratory instruments, allowing for bundled sales of reagents and instruments, thus creating a synergistic effect [2]. - The valuation for the stake in Shanghai Youke is considered reasonable, with a PE ratio of approximately 7.8 times and a PB ratio of about 1.8 times, indicating a solid investment opportunity [3]. - Aladdin's revenue and profit forecasts for 2025-2027 show significant growth, with projected revenues of 6.49 billion, 8.60 billion, and 9.64 billion respectively, and net profits of 0.96 billion, 1.46 billion, and 1.70 billion [3]. Financial Summary - Total revenue for 2023 is reported at 403 million, with a year-on-year growth rate of 6.6%. This is expected to increase to 534 million in 2024, representing a growth rate of 32.4% [4]. - The net profit for 2023 is 86 million, with a projected decline of 7.5% year-on-year, but is expected to recover to 99 million in 2024, reflecting a growth of 15.1% [4]. - The gross margin is forecasted to remain stable around 62.6% to 62.9% from 2025 to 2027, indicating strong operational efficiency [4].

Group 1 - The core point of the news is that Lidman Biochemical Co., Ltd. has seen a stock price increase of 5.46%, reaching 11.39 CNY per share, with a total market capitalization of 6.196 billion CNY [1] - The company is located in Beijing Economic and Technological Development Zone and focuses on the research and production of biochemical reagents, operating 10 subsidiaries and a nationwide distribution network [1] - Lidman has a daily production capacity of 4000 liters and aims to advance biological sciences and improve the quality of life for people [1] Group 2 - As of July 31, the number of shareholders for Lidman is 17,000, with an average of 31,900 circulating shares per person [2] - For the first quarter of 2025, Lidman reported operating revenue of 78.9087 million CNY, a year-on-year decrease of 16.61%, while the net profit attributable to shareholders was -1.2517 million CNY, reflecting a year-on-year increase of 53.73% [2]

Core Viewpoint - Lidman Biochemical Co., Ltd. has shown a significant stock price increase and is actively engaged in the development and production of biochemical reagents, aiming to enhance the quality of life and advance biological sciences [1][2]. Group 1: Stock Performance - On August 12, Lidman’s stock rose by 5.47%, reaching a price of 11.18 yuan per share, with a trading volume of 2.11 billion yuan and a turnover rate of 3.59%, resulting in a total market capitalization of 60.82 billion yuan [1]. Group 2: Company Overview - Lidman is located in Beijing Economic and Technological Development Zone and operates 10 subsidiaries along with a nationwide distribution network, achieving a daily production capacity of 4000 liters [1]. - The company is committed to promoting advancements in biological sciences and improving the quality of life for people, having established a business organization across the country to better understand market trends and meet customer needs [1]. Group 3: Financial Performance - As of July 31, Lidman had 17,000 shareholders, with an average of 31,900 circulating shares per person [2]. - For the first quarter of 2025, Lidman reported operating revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, while the net profit attributable to shareholders was -1.25 million yuan, reflecting a year-on-year increase of 53.73% [2].